NEW YORK (GenomeWeb) – Affymetrix's third quarter revenues increased 8 percent year over year, the company reported after the close of the market on Thursday.

For the three months ended Sept. 30, total revenues improved to $87.1 million from $80.4 million in Q3 2013, beating the consensus Wall Street estimate of $84.4 million.

Product sales were up to $78.1 million from $74.8 million a year ago, while services and other revenues increased to $9 million from $5.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.